Table S2.
Flow cytometric analysis of Jurkat cell cycle after treatment with ZER-NLC
| Cell cycle phase | Cells (%)
|
|||||||
|---|---|---|---|---|---|---|---|---|
| 12 hours
|
24 hours
|
48 hours
|
72 hours
|
|||||
| Control | ZER-NLC | Control | ZER-NLC | Control | ZER-NLC | Control | ZER-NLC | |
| G0/G1 | 59.81±0.82 | 40.44±0.58 | 52.81±0.68 | 34.09±0.5 | 62.73±0.57 | 38.28±0.32 | 58.7±0.59 | 32.42±0.83 |
| G2/M | 18.38±0.53 | 35.46±0.49* | 21.43±0.84 | 40.14±0.75* | 15.36±0.55 | 34.91±1.22* | 10.64±0.31 | 24.59±2.5* |
| S | 21.51±0.47 | 22.83±0.08 | 24.79±0.33 | 24.46±0.35 | 19.81±0.32 | 21.83±0.5 | 21.75±0.69 | 21.45±1.2 |
| SubG0/G1 | 0.81±0.07 | 1.39±0.06 | 1.56±0.09 | 1.99±0.64 | 2.47±0.24 | 5.52±0.47 | 9.27±0.67 | 22.12±0.76 |
Notes: Cells were stained with propidium iodide and incubated at 37°C for 24, 48, and 72 hours. Values are expressed as the mean ± standard deviation of three different experiments. The data were analyzed using post hoc comparison test-one way analysis of variance, and the means were compared by Tukey’s b test.
*
Significant (P<0.05) increase in cells in G2/M phase in ZER-NLC-treated group versus untreated control.
Abbreviation: ZER-NLC, zerumbone-loaded nanostructured lipid carrier.